Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up

Retina

Volumn 33, Issue 2, 2013, Pages 329-338

  Martínez Castellanos, María A ^a   Schwartz, Shulamit ^b   Hernández Rojas, Myriam L ^a   Kon Jara, Veronica A ^a   García Aguirre, Gerardo ^a   Guerrero Naranjo, José L ^a   Chan, R V Paul ^c   Quiroz Mercado, Hugo ^b  

^a HOSPITAL DR LUIS SÁNCHEZ BULNES   (Mexico)

^b DENVER HEALTH MEDICAL CENTER   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

anti vascular endothelial growth factor (VEGF); antiangiogenic; bevacizumab; retinopathy of prematurity (ROP)

Indexed keywords

BEVACIZUMAB;

ANTIANGIOGENIC THERAPY; ARTICLE; BIRTH WEIGHT; CASE STUDY; CHILD GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CONVERGENT STRABISMUS; CRYOTHERAPY; ELECTRORETINOGRAPHY; EYE FUNDUS; FEMALE; FOLLOW UP; GESTATIONAL AGE; GROWTH RETARDATION; HUMAN; INFANT; INTERVENTION STUDY; LENSECTOMY; LONG TERM CARE; MALE; MONOCULAR VISION; MYOPIA; NERVE CELL DIFFERENTIATION; OUTCOME ASSESSMENT; PARACENTESIS; PROSPECTIVE STUDY; REFRACTION ERROR; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; SPECTACLES; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMETRY; BIRTH WEIGHT; CHILD, PRESCHOOL; ELECTRORETINOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RECURRENCE; REFRACTION, OCULAR; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84873408269     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318275394a     Document Type: Article

References (54)

1. Gilbert C, Rahi J, Eckstein M, Foster A. Retinopathy of prematurity in middle-income countries. Lancet 1997;350:12-14.
2. Hutchenson KA, Kelly A. Retinopathy of prematurity. Curr Opin Ophthalmol 2003;14:286-290.
3. Earl A, Palmer MD, John T, et al. Incidence and early course of retinopathy of prematurity. Ophthalmology 1991;98:1628-1639.
4. Steinkuller PG, Du L, Gilbert C, et al. Childhood blindness. J AAPOS 1999;3:26-32.
5. Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol 2009;148:451-458.
6. Gilbert C. Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008;84:77-82.
7. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: Preliminary results. Arch Ophthalmol 1988;106: 471-479.
8. Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004;102:233-248.
9. Fielder AR, Shaw ED, Robinson J, Yin K. Natural history of retinopathy of prematurity: A prospective study. Eye 1992;6: 233-242.
10. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci 1993;34:576-585.
11. Pierce EA, Foley ED, Smith LEH. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114:1219-1228.
12. Smith LE. Through the eyes of a child: Understanding retinopathy through ROP. Invest Ophthalmol Vis Sci 2008;49:5177-5182.
13. Lashkari K, Hirose T, Yazdany J, et al. Vascular endothelial growth and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000;156:1337-1344.
14. Pieh C, Agostini H, Buschbeck C, et al. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: Relationship to retinopathy of prematurity. Br J Ophthalmol 2008;92:689-693.
15. Madan A. Angiogenesis and antiangiogenesis in the neonate: Relevance to retinopathy of prematurity. Neoreviews 2003;4: 456-464.
16. Villegas B, Gonzalez F, Fernandez M. Growth factor levels and ROP. Ophthalmology 2005;112:2238.
17. Stone J, Itim A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738-4747.
18. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
19. Stone J, Chan-Ling T, Pe'er J, et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996; 37:290-299.
20. Mintz H, Kuffel R. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in one I or posterior zone II. Retina 2008;28:831-838.
21. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28 (suppl):S19-S25.
22. Lalwani G, Berrocal A, Murray T, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008;28:S13-S18.
23. Quiroz-Mercado H, Ustariz-González O, Martinez-Castellanos MA, et al. Our experience after 1765 intravitreal injections of bevacizumab: The importance of being part of a developing story. Semin Ophthalmol 2007;22:109-125.
24. Orozco-Gomez LP, Hernandez-Salazar L, Moguel-Ancheita S. Laser-ranibizumab treatment for retinopathy of prematurity in threshold-prethreshold disease. A 3-year experience [in Spanish]. Cir Cir 2011;79:207-214.
25. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;64: 603-615.
26. Raizada S, Kandari JA, Sabti KA. Will the BEAT-ROP study results really beat ROP? Invest Ophthalmol Vis Sci 2011;52: 9288-9289.
27. Darlow BA, Ells AL, Gilbert CE, et al. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed Dec 30, 2011. Epub ahead of print
28. Section of Ophthalmology American Association of Pediatrics. American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006;117:572-576.
29. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991-999.
30. Frankenburg WK, Dodds J, Archer P, et al. The Denver II: A major revision and restandardization of the Denver Developmental Screening Test. Pediatrics 1992;89:91-97.
31. Council on Children With Disabilities; Section on Developmental Behavioral Pediatrics; Bright Futures Steering Committee; Medical Home Initiatives for Children With Special Needs Project Advisory Committee. Identifying infants and young children with developmental disorders in the medical home: An algorithm for developmental surveillance and screening. Pediatrics 2006;118:405-420.
32. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: Results of the Early Treatment for Retinopathy of Prematurity randomized trial. Arch Ophthalmol 2003;121:1684-1694.
33. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity; ophthalmological outcome 10 years. Arch Ophthalmol 2001;119:1110-1118.
34. Palmer EA, Hardy RJ, Dobson V, et al; Cryotherapy for Retinopathy of Prematurity Cooperative Group. 15-year outcomes following threshold retinopathy of prematurity: Final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 2005;123:311-318.
35. Tufail A, Singh AJ, Haynes RJ, Dodd RJ. Late onset vitreoretinal complications of regressed retinopathy of prematurity. Br J Ophthalmol 2004;88:243-246.
36. Laws F, Laws D, Clark D. Cryotherapy and laser treatment for acute retinopathy of prematurity: Refractive outcomes, a longitudinal study. Br J Ophthalmol 1997;81:12-15.
37. Cuthbertson F, Nerwsom R. UK retinopathy of prematurity treatment survey. Eye 2006;7:76-81.
38. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 2009;148:536-543.
39. Shalev B, Farr AK, Repka MX. Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: Seven-year outcome. Am J Ophthalmol 2001;132:76-80.
40. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development 1999;126: 1149-1159.
41. Carneiro AM, Costa R, Falcão MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012;90:e25-e30.
42. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327-333.
43. Glade-Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors. A Children's Oncology Group Study. J Clin Oncol 2008;26:399-405.
44. Böcker-Meffert S, Rosenstiel P, Röhl C, et al. Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats. Invest Ophthalmol Vis Sci 2002;43:2021-2026.
45. Cook A, White S, Batterbury M, Clark D. Ocular growth and refractive error development in premature infants with or without retinopathy of prematurity. Invest Ophthalmol Vis Sci 2008;49:5199-5207.
46. Choi MY, Park IK, Yu YS. Long term refractive outcome in eyes of preterm infants with and without retinopathy of prematurity: Comparison of keratometric value, axial length, anterior chamber depth, and lens thickness. Br J Ophthalmol 2000; 84:138-143.
47. Quinn GE, Dobson V, Davitt BV, et al; Early Treatment for Retinopathy of Prematurity Cooperative Group. Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: Findings to 3 years of age. Ophthalmology 2008;115:1058-1064.e1.
48. Sahni J, Subhedar NV, Clark D. Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: A study of motility, refractive, and anatomical outcomes at 6 months and 36 months. Br J Ophthalmol 2005;89:154-159.
49. McLoone EM, O'Keefe M, McLoone SF, Lanigan BM. Longterm refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity. J AAPOS 2006;10: 454-459.
50. Chen TC, Tsai TH, Shih YF, et al. Long-term evaluation of refractive status and optical components in eyes of children born prematurely. Invest Ophthalmol Vis Sci 2010;51:6140-6148.
51. Fulton AB, Hansen RM, Moskowitz A. The cone electroretinogram in retinopathy of prematurity. Invest Ophthalmol Vis Sci 2008;49:814-819.
52. Cherry AT, Scott B, Lambert R, Capone A. Electroretinographic findings in stage 5 retinopathy of prematurity after retinal reattachment. Retina 1995;15:21-24.
53. Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birthweight infants with neonatal infection. JAMA 2004;292: 2357-2365.
54. Belfort MB, Rifas-Shiman SL, Sullivan T, et al. Infant growth before and after term: Effects on neurodevelopment in preterm infants. Pediatrics 2011;128:e899-e906.